- Home
- BMBL vs DCTH Comparison
BMBL vs DCTH Comparison
Compare BMBL & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | DCTH |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 350.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BMBL | DCTH |
|---|---|---|
| Price | $3.58 | $10.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $4.83 | ★ $22.60 |
| AVG Volume (30 Days) | ★ 2.9M | 486.6K |
| Earning Date | 02-17-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $1,003,141,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $131.69 |
| Revenue Next Year | N/A | $39.22 |
| P/E Ratio | ★ N/A | $292.70 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $3.18 | $8.12 |
| 52 Week High | $8.82 | $18.23 |
Technical Indicators
Market Signals| Indicator | BMBL | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 54.49 |
| Support Level | $3.43 | $9.98 |
| Resistance Level | $3.62 | $10.37 |
| Average True Range (ATR) | 0.18 | 0.38 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 49.53 | 36.36 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.